News GSK makes fresh neuroscience foray with £2bn+ ABL deal Neuroscience isn't listed as one of the top R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting.
R&D Manufacturing gene therapies, oncolytic viruses, and vaccine... The Alliance for Regenerative Medicine’s (ARM) Cell & Gene Meeting on the Med, took place in Barcelona back in April.
News Sanofi places $75m bet with ABL on popular Parkinson's drug ... Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson's disease, licensing a bispecific antibody from South Korea's ABL Bio in a deal that
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.